- Press Release -

Rockville, Md. The global aptamers market is set to grow at a 25.5% CAGR through 2022, according to Fact.MR, propelled by advances in technology, rising biopharmaceutical investment and the expiry of key SELEX patents. Because aptamers can be generated far faster than antibodies, they are increasingly valuable in drug discovery, underpinning their rapid adoption.

North America is the most lucrative region, DNA aptamers lead by product, and diagnostics is the largest application. Peptide aptamers and research uses are the fastest-growing pockets.

Products, Applications and End Users

DNA aptamers hold the largest revenue share in 2017, but peptide aptamers grow fastest at a 30.1% CAGR, while XNA and RNA aptamers post similar growth rates. By application, diagnostics holds the larger revenue share, with research and development growing quickest at a 26.5% CAGR ahead of therapeutics. Among end users, biopharmaceutical companies dominate revenue, while academic and research centers grow fastest at a 26.4% CAGR, and pharmaceutical companies and contract research organizations expand in step.

North America leads all regions at a 26.3% CAGR, supported by a high level of technological development and heavy R&D investment.

Drug Discovery Drives Demand

The market runs on speed and utility. Aptamers' quick generation and versatility make them attractive across diagnostics, therapeutics and research, and expiring SELEX patents are opening the field to more participants, sustaining exceptional growth through the forecast period.

Suppliers and Their Playbook

The field brings together specialist aptamer and biotech firms.

• Vivonics Inc., TriLink BioTechnologies, LLC, Somalogic, Inc., NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC, and AM Biotech are among the key players in the report.

Reading the Market for Decisions

For developers, growth favours peptide aptamers and research-oriented applications. Investors get a small but fast-expanding market with a strong innovation tailwind. Procurement and research teams can plan around DNA aptamers carrying volume, diagnostics leading applications, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global aptamers market for the 2017 to 2022 forecast period, with segmentation by product type, application, end user and region. It sizes each segment, maps the competitive field, and weighs the innovation forces shaping demand. Further detail is available in the aptamers market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.